SCHEMBL5519630

SCHEMBL5519630

CC1(c2ccc(F)cc2)OC=CC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 7/20 0.53
HCAR3 P49019 6/20 0.53
CYP1A2 P05177 1/20 0.38
CACNA1B Q00975 1/20 0.34
APBA1 Q02410 1/20 0.34
DRD2 P14416 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
ALDH1A1 P00352 2/20 0.33
TSHR P16473 1/20 0.33
CHRNA1 P02708 1/20 0.32
CHRNG P07510 1/20 0.32
CHRNB1 P11230 1/20 0.32
CHRNB2 P17787 1/20 0.32
SLC6A2 P23975 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CHRND Q07001 1/20 0.32
MGLL Q99685 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531379 0.82 HCAR2 (0.55) HCAR2HCAR3CYP1A2CHRNA1CHRNG
SCHEMBL11414250 0.82 HCAR2 (0.53) HCAR2HCAR3CYP1A2DRD2SIGMAR1
SCHEMBL5522028 0.78 HCAR2 (0.57) HCAR2HCAR3CYP1A2ALDH1A1
SCHEMBL5521792 0.76 HCAR2 (0.51) HCAR2HCAR3CYP1A2DRD2SIGMAR1
SCHEMBL3101214 0.73 HCAR2 (0.56) HCAR2HCAR3CYP1A2CACNA1BAPBA1
SCHEMBL5526802 0.73 HCAR2 (0.54) HCAR2HCAR3CYP1A2DRD2SIGMAR1
SCHEMBL5520638 0.72 HCAR2 (0.40) HCAR2HCAR3CYP1A2DRD2SIGMAR1
SCHEMBL5531839 0.72 HCAR2 (0.57) HCAR2HCAR3CYP1A2DRD2SIGMAR1
SCHEMBL3100197 0.72 HCAR2 (0.57) HCAR2HCAR3CYP1A2DRD2SIGMAR1
SCHEMBL3100362 0.70 HCAR2 (0.43) HCAR2HCAR3CYP1A2DRD2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093545-A1 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof ARENA PHARMACEUTICALS, INC. (US) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093545-A1 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof ABAT, G6PD, GLS2 HCAR2 229/4885HCAR3 373/4885CYP1A2 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.